The contingent value right (CVR) offered by BMS as a sweetener for the $74 billion takeover of Celgene in 2019 is defunct, as one of the three drugs – CAR-T therapy liso-cel for lymphoma ...

The headline news is that Celgene chief executive Mark Alles is heading for the door, and there’s also no room for BMS’ recently-appointed chief scientific officer Thomas Lynch in the combined ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...